Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Curr Top Microbiol Immunol. 2011;344:173–192. doi: 10.1007/82_2010_48

Figure 4.

Figure 4

DC vaccines in combination therapies. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current approaches is limited, possibly because tumors invade the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs). To improve the clinical efficacy of immunotherapies, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of an immunosuppressive tumor microenvironment. This can be achieved by developing combination therapies targeting these three major components.